STOCK TITAN

Valion Bio gets 1-for-2 to 1-for-12 reverse split authority

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Valion Bio, Inc. (VBIO) stockholders approved a 272,000-share increase in the common-stock reserve authorized for issuance under the 2021 Equity Incentive Plan; the amendment took effect upon approval on November 12, 2026. Stockholders also authorized the board to amend the certificate of incorporation to effect a reverse stock split at a ratio from 1-for-2 to 1-for-12. The board may select the ratio within 12 months of approval without further stockholder approval. Stockholders also approved authority for the board to adjourn the special meeting to solicit additional proxies if necessary or appropriate.

As of October 15, 2026, 2,155,637 common shares were issued and outstanding and entitled to vote. A total of 1,125,685 shares, approximately 52.22% of those entitled to vote, were represented at the meeting. Series A, Series B and Series C Non-Voting Convertible Preferred Stock were not entitled to vote on the proposals.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
2021 Plan share-reserve increase 272,000 shares Approved by stockholders on November 12, 2026; effective upon approval
Authorized reverse split ratio range 1-for-2 to 1-for-12 Ratio to be selected by the board within 12 months of stockholder approval
Common shares issued and outstanding and entitled to vote 2,155,637 shares As of October 15, 2026
Shares represented at special meeting 1,125,685 shares Represented virtually or by proxy
Shares represented as a portion of shares entitled to vote Approximately 52.22% Special meeting quorum
Reverse split authorization votes for 681,523 votes Proposal 1
Reverse split authorization votes against 444,153 votes Proposal 1
Reverse split authorization abstentions 9 votes Proposal 1
reverse stock split technical
"effect a reverse stock split at a ratio"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
quorum regulatory
"constituting a quorum"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
record date regulatory
"the record date for the Special Meeting"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
broker non-votes technical
"Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
authorized for issuance technical
"shares of common stock authorized for issuance thereunder"
Non-Voting Convertible Preferred Stock technical
"Series A, Series B and Series C Non-Voting Convertible Preferred Stock"
A non-voting convertible preferred stock is a share that normally pays a fixed dividend and takes priority over common stock for payouts, but does not grant the holder the right to vote on corporate matters. It can be exchanged later for a set number of common shares, offering the potential to participate in price gains without immediate control—like holding a high-yield loan that can be turned into equity, which matters to investors weighing steady income, upside potential, and possible dilution of ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was the vote on VBIO’s reverse stock split authorization?

Stockholders approved the authorization with 681,523 votes for, 444,153 against and 9 abstentions; there were no broker non-votes.

How much did VBIO increase its 2021 Plan share reserve?

Stockholders approved an increase of 272,000 common shares authorized for issuance under the 2021 Equity Incentive Plan, effective upon stockholder approval on November 12, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001787740 0001787740 2026-11-12 2026-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 12, 2026

 

 

Valion Bio, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware 001-41052 81-4016391
(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)
     

1305 E. Houston Street,

Building 1, Suite 311

   
San Antonio, Texas   78205
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 888 276-6888

 

Not applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)  
Name of each exchange on which registered
Common Stock, par value $0.0001 per share   VBIO   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

   

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On November 12, 2026, the stockholders of Valion Bio, Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated 2021 Equity Incentive Plan (the “2021 Plan”) to increase the number of shares of common stock authorized for issuance thereunder by 272,000 shares (the “Plan Amendment”). The Plan Amendment became effective upon stockholder approval. Except for the increase in the share reserve and related conforming changes, the Plan Amendment did not change any other term or provision of the 2021 Plan.

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On November 12, 2026, the Company held a special meeting of stockholders in a virtual format (the “Special Meeting”). As of the close of business on October 15, 2026, the record date for the Special Meeting, there were 2,155,637 shares of the Company’s common stock issued and outstanding and entitled to vote. At the Special Meeting, 1,125,685 shares, or approximately 52.22% of the shares entitled to vote, were represented virtually or by proxy, constituting a quorum. Holders of the Company’s Series A, Series B and Series C Non-Voting Convertible Preferred Stock were not entitled to vote those shares on the matters presented at the Special Meeting.

 

The proposals are more fully described in the Company’s Definitive Proxy Statement on Schedule 14A dated October 16, 2026 (the “Proxy Statement”). The description of the 2021 Plan and the Plan Amendment under Proposal 2 in the Proxy Statement is incorporated by reference into Item 5.02 of this Current Report.

 

Based on the final tabulation provided by Broadridge, the voting results on the proposals presented at the Special Meeting were as follows:

 

Proposal No. 1: The Company’s stockholders approved the proposal to grant discretionary authority to the Company’s board of directors (the “Board”) to amend the Company’s amended and restated certificate of incorporation to effect a reverse stock split of all issued and outstanding shares of common stock at a ratio of not less than 1-for-2 and not greater than 1-for-12, with the ratio to be determined by the Board at any time within twelve months from the date of stockholder approval, without further stockholder approval or authorization.

 

Votes For Votes Against Abstentions Broker Non-Votes
681,523 444,153 9 0

 

Proposal No. 2: The Company’s stockholders approved the Plan Amendment to increase the number of shares of common stock authorized for issuance under the 2021 Plan by 272,000 shares.

 

Votes For Votes Against Abstentions Broker Non-Votes
466,174 131,057 27 528,427

 

Proposal No. 3: The Company’s stockholders approved the proposal to authorize the Board, in its discretion, to adjourn the Special Meeting to another place, or a later date or dates, if necessary or appropriate, to solicit additional proxies in favor of the foregoing proposals.

 

Votes For Votes Against Abstentions Broker Non-Votes
686,478 438,311 896 0

 

 

 

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      VALION BIO, INC.
       
Date: November 16, 2026 By: /s/ Dean Zikria
      Name: Dean Zikria
Title: Interim Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 

 

Filing Exhibits & Attachments

3 documents

Keep reading